BioCentury | Jan 13, 2021
Regulation

Jan. 12 Quick Takes: U.S. releases all doses of mRNA vaccines; more Regeneron mAb under HHS deal, plus Black Diamond

Azar says all COVID vaccine doses releasedHHS Secretary Alex Azar said Tuesday on Good Morning America that every dose of Moderna COVID-19 Vaccine from Moderna Inc. (NASDAQ:MRNA) and Comirnaty from Pfizer Inc. (NYSE:PFE) and BioNTech...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...– C-Met receptor tyrosine kinaseCSF1R (C-FMS; CD115) – Colony-stimulating factor 1 receptorKRAS (K-Ras) – KRAS proto-oncogene...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...immunoreceptor with Ig and ITIM domains (TIGIT) KRAS proto-oncogene...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...factor subunit RAB22A - RAB22A member RAS oncogene...
...albicansYCK2) MAGE family member A11 (MAGEA11) RAB22A member RAS oncogene...
BioCentury | Dec 17, 2020
Finance

New Italian VC’s first play is Spanish biotech chasing notoriously difficult target

...placed its first marker on a company going after one of life sciences’ most infamous oncogene...
...MYC associated factor XMYC (c-Myc) – v-myc myelocytomatosis viral oncogene homolog Stephen Hansen Peptomyc S.L. v-myc myelocytomatosis viral oncogene...
BioCentury | Dec 15, 2020
Deals

Genentech gets competitive in KRAS with early dealmaking push: Data Byte

...tyrosine phosphatase 2 Lauren Martz RLY-1971 Genentech Inc. Relay Therapeutics Inc. KRAS proto-oncogene...
BioCentury | Dec 7, 2020
Product Development

Loxo to take on Imbruvica after reversible Btk inhibitor shines at ASH

...thyroid cancers that was the anchor of the deal.TARGETSBtk – Bruton’s tyrosine kinaseRET – Ret proto-oncogene Lauren...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting BMI1 and BCL-2 to treat diffuse intrinsic pontine glioma

...acute myelogenous leukemia (AML), leiomyosarcoma, ovarian cancer and other solid tumors.TARGET/MARKER/PATHWAY: BMI1 polycomb ring finger oncogene...
...Colo.email: rajeev.vibhakar@cuanschutz.edu CONTACT: Sujatha Venkataraman, same affiliation as aboveemail: sujatha.venkataraman@cuanschutz.edu Claire Quang University of Colorado Denver BMI1 polycomb ring finger oncogene...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...– Neuropilin 1RAB7A – RAB7A member RAS oncogene...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

AstraZeneca’s oncology R&D chief José Baselga sees the pharma’s push into ADCs as prologue for its quiet move into cell therapies, as the company builds up a stable of new modalities and targets...
Items per page:
1 - 10 of 1902
BioCentury | Jan 13, 2021
Regulation

Jan. 12 Quick Takes: U.S. releases all doses of mRNA vaccines; more Regeneron mAb under HHS deal, plus Black Diamond

Azar says all COVID vaccine doses releasedHHS Secretary Alex Azar said Tuesday on Good Morning America that every dose of Moderna COVID-19 Vaccine from Moderna Inc. (NASDAQ:MRNA) and Comirnaty from Pfizer Inc. (NYSE:PFE) and BioNTech...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...– C-Met receptor tyrosine kinaseCSF1R (C-FMS; CD115) – Colony-stimulating factor 1 receptorKRAS (K-Ras) – KRAS proto-oncogene...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...immunoreceptor with Ig and ITIM domains (TIGIT) KRAS proto-oncogene...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...factor subunit RAB22A - RAB22A member RAS oncogene...
...albicansYCK2) MAGE family member A11 (MAGEA11) RAB22A member RAS oncogene...
BioCentury | Dec 17, 2020
Finance

New Italian VC’s first play is Spanish biotech chasing notoriously difficult target

...placed its first marker on a company going after one of life sciences’ most infamous oncogene...
...MYC associated factor XMYC (c-Myc) – v-myc myelocytomatosis viral oncogene homolog Stephen Hansen Peptomyc S.L. v-myc myelocytomatosis viral oncogene...
BioCentury | Dec 15, 2020
Deals

Genentech gets competitive in KRAS with early dealmaking push: Data Byte

...tyrosine phosphatase 2 Lauren Martz RLY-1971 Genentech Inc. Relay Therapeutics Inc. KRAS proto-oncogene...
BioCentury | Dec 7, 2020
Product Development

Loxo to take on Imbruvica after reversible Btk inhibitor shines at ASH

...thyroid cancers that was the anchor of the deal.TARGETSBtk – Bruton’s tyrosine kinaseRET – Ret proto-oncogene Lauren...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting BMI1 and BCL-2 to treat diffuse intrinsic pontine glioma

...acute myelogenous leukemia (AML), leiomyosarcoma, ovarian cancer and other solid tumors.TARGET/MARKER/PATHWAY: BMI1 polycomb ring finger oncogene...
...Colo.email: rajeev.vibhakar@cuanschutz.edu CONTACT: Sujatha Venkataraman, same affiliation as aboveemail: sujatha.venkataraman@cuanschutz.edu Claire Quang University of Colorado Denver BMI1 polycomb ring finger oncogene...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...– Neuropilin 1RAB7A – RAB7A member RAS oncogene...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

AstraZeneca’s oncology R&D chief José Baselga sees the pharma’s push into ADCs as prologue for its quiet move into cell therapies, as the company builds up a stable of new modalities and targets...
Items per page:
1 - 10 of 1902